AstraZeneca Acquires Omniose, Adding Bioconjugation Technology to Vaccine Development Capabilities
Key Points
- AstraZeneca acquired Omniose after a three-year collaboration; Omniose becomes a wholly owned subsidiary in its Infectious Disease Unit.
- Omniose's bioconjugation platform produces and links conjugate vaccine components in a single cell, simplifying manufacturing versus multistep chemical processes.
- The platform strengthens AstraZeneca's bacterial vaccine development amid rising antimicrobial resistance.
AstraZeneca has acquired Omniose, a preclinical-stage biotechnology company developing next-generation bioconjugation technologies, following a three-year exclusive research collaboration between the two organizations. As part of the transaction, Omniose will become a wholly owned subsidiary of AstraZeneca within its Infectious Disease Unit. The acquisition brings Omniose’s proprietary bioconjugation platform and scientific expertise into AstraZeneca’s research organization, with the technology expected to complement the pharmaceutical company’s existing capabilities in bacterial vaccine development.
Omniose’s platform is designed to offer an alternative to conventional methods used to manufacture conjugate vaccines. These vaccines work by linking bacterial polysaccharides to carrier proteins to stimulate an immune response. Traditionally, the components are produced separately and connected through multistep chemical processes.
Omniose’s approach uses bioconjugation to produce and link the components within a single cell. By integrating these steps, the platform could simplify manufacturing, provide greater control over molecular design and support the development of more precisely engineered conjugate vaccines.
The technology adds another tool to AstraZeneca’s efforts to develop vaccines targeting serious bacterial infections, an area of increasing concern as antimicrobial resistance continues to complicate treatment options.
Christian Harding, chief scientific officer and co-founder of Omniose, says the acquisition reflects the complementary expertise developed through the companies’ collaboration. He notes that the relationship with AstraZeneca has provided a strong foundation for the technology and that joining the company creates an opportunity to advance the platform toward clinical applications and ultimately patients.
Benjamin Moutier, senior vice president of Infectious Disease at AstraZeneca, says Omniose’s technology offers a differentiated approach to conjugate vaccine engineering. He explains that bringing the platform into AstraZeneca strengthens its research capabilities and creates opportunities to advance new vaccine candidates targeting bacterial infections.
Visit www.omniose.com for more information.
Total Page Views: 4
